论文部分内容阅读
目的探讨含铋四联疗法联合双歧杆菌四联活菌片抗幽门螺杆菌(Hp)作用及其对消化性溃疡的疗效和安全性。方法选取就诊于我院的消化性溃疡患者129例,采用随机分组法将患者分为观察组(n=66)和对照组(n=63)。对照组采用基于抗幽门螺杆菌的含铋四联疗法(雷贝拉唑+阿莫西林+克拉霉素+枸橼酸铋钾),观察组在对照组基础上加用双岐杆菌四联活菌片,两组疗程均为2周。观察并记录两组总有效率及Hp根除率,治疗6个月后随访Hp复发率,并观察两组不良反应。结果治疗后,观察组在Hp根除率、总有效率、复发率方面均优于对照组(P<0.05或0.01),两组不良反应发生情况差异无统计学意义(P>0.05)。结论含铋四联疗法联合双歧杆菌四联活菌治疗Hp引起的消化性溃疡疗效可靠,安全性好,值得临床推广应用。
Objective To investigate the anti-Helicobacter pylori (Hp) effect of bismuth-containing quadruple therapy combined with Bifidobacterium quadriceps and its efficacy and safety on peptic ulcer. Methods A total of 129 patients with peptic ulcer were enrolled in our hospital. Patients were divided into observation group (n = 66) and control group (n = 63) by random grouping method. The control group was based on the anti-Helicobacter pylori-containing bismuth quadruple therapy (rabeprazole + amoxicillin + clarithromycin + bismuth potassium citrate), the observation group in the control group plus Bifidobacterium quadruple live Bacterial films, two groups of treatment are 2 weeks. The total effective rate and Hp eradication rate were observed and recorded. The recurrence rate of Hp was observed after 6 months treatment, and two groups of adverse reactions were observed. Results After treatment, the observation group was better than the control group in the eradication rate, total effective rate and recurrence rate (P <0.05 or 0.01). There was no significant difference in adverse reaction between the two groups (P> 0.05). Conclusions Bismuth-containing quadruple therapy combined with Bifidobacterium quadriceps can treat peptic ulcer caused by Hp is reliable, safe and worthy of clinical application.